ConductScience.org, home

Paper41399804

Validation of an algorithm for selection of SGLT2 and DPP4 inhibitor therapies in people with type 2 diabetes across major UK ethnicity groups: a retrospective cohort study.

Güdemann LM and 11 others. Lancet Reg Health Eur, 2026. Cited by 3 papers, by iCite.

Cite this record

ConductScience Library. Validation of an algorithm for selection of SGLT2 and DPP4 inhibitor therapies in people with type 2 diabetes across major UK ethnicity groups: a retrospective cohort study. Papers, record 41399804. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/41399804

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Validation of an algorithm for selection of SGLT2 and DPP4 inhibitor therapies in people with type 2 diabetes across major UK ethnicity groups: a retrospective cohort study.
PubMed
Journal
Lancet Reg Health Eur
PubMed
Year
2026
PubMed
Publication types
Journal Article
PubMed
Citations, by iCite
3
iCite
Revised in PubMed
2025-12-18
PubMed

Authors12

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Güdemann LMLaura M
2Young KGKatherine G
3Cardoso PPedro
4Mateen BABilal A
5Holman RRRury R
6Sattar NNaveed
7Pearson EREwan R
8Hattersley ATAndrew T
9Jones AGAngus G
10Shields BMBeverley M
11Dennis JMJohn M
12MASTERMIND ConsortiumGroup

Source PubMed

Download CSV of authors

Topics0

NLM's MeSH indexing of the paper, its major topics first.

None in this release.

References28

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
124323951Completeness and usability of ethnicity data in UK-based primary care and hospital databases.J Public Health (Oxf)2014https://conductscience.org/library/papers/24323951PubMed
232821142SGLT2 Inhibitors as Add-On Therapy to Metformin for People with Type 2 Diabetes: A Review of Placebo-Controlled Trials in Asian versus Non-Asian Patients.Diabetes Metab Syndr Obes2020https://conductscience.org/library/papers/32821142PubMed
330008267
Changes in HbA1c and weight, and treatment persistence, over the 18 months following initiation of second-line therapy in patients with type 2 diabetes: results from the United Kingdom Clinical Practice Research Datalink.
BMC Med2018https://conductscience.org/library/papers/30008267PubMed
436515129
Cardiometabolic risk reductions in patients with type 2 diabetes mellitus newly treated with a sodium-glucose cotransporter 2 inhibitor versus a dipeptidyl peptidase-4 inhibitor: A real-world administrative database study in Japan.
J Diabetes Investig2023https://conductscience.org/library/papers/36515129PubMed
536427949Development of a treatment selection algorithm for SGLT2 and DPP-4 inhibitor therapies in people with type 2 diabetes: a retrospective cohort study.Lancet Digit Health2022https://conductscience.org/library/papers/36427949PubMed
639427028Guidance for unbiased predictive information for healthcare decision-making and equity (GUIDE): considerations when race may be a prognostic factor.NPJ Digit Med2024https://conductscience.org/library/papers/39427028PubMed
727891652A closed testing procedure to select an appropriate method for updating prediction models.Stat Med2017https://conductscience.org/library/papers/27891652PubMed
828834075Therapeutic inertia in the treatment of hyperglycaemia in patients with type 2 diabetes: A systematic review.Diabetes Obes Metab2018https://conductscience.org/library/papers/28834075PubMed
938126004Use of the CPRD Aurum Database: Insights Gained from New Data Quality Assessments.Clin Epidemiol2023https://conductscience.org/library/papers/38126004PubMed
1032744394Cardiometabolic risk factor control in black and white people in the United States initiating sodium-glucose co-transporter-2 inhibitors: A real-world study.Diabetes Obes Metab2020https://conductscience.org/library/papers/32744394PubMed
1125043156Efficacy of dipeptidyl-peptidase-4 inhibitors and impact on β-cell function in Asian and Caucasian type 2 diabetes mellitus patients: A meta-analysis.J Diabetes2015https://conductscience.org/library/papers/25043156PubMed
1236238229Weight changes following antidiabetic mediation use: Real-world evidence from health system data.Obes Sci Pract2022https://conductscience.org/library/papers/36238229PubMed
1337794166Treatment effect heterogeneity following type 2 diabetes treatment with GLP1-receptor agonists and SGLT2-inhibitors: a systematic review.Commun Med (Lond)2023https://conductscience.org/library/papers/37794166PubMed
1432843566Precision Medicine in Type 2 Diabetes: Using Individualized Prediction Models to Optimize Selection of Treatment.Diabetes2020https://conductscience.org/library/papers/32843566PubMed
1529316164
Effects of exenatide once weekly plus dapagliflozin, exenatide once weekly, or dapagliflozin, added to metformin monotherapy, on body weight, systolic blood pressure, and triglycerides in patients with type 2 diabetes in the DURATION-8 study.
Diabetes Obes Metab2018https://conductscience.org/library/papers/29316164PubMed
1629029369No disparity of the efficacy and all-cause mortality between Asian and non-Asian type 2 diabetes patients with sodium-glucose cotransporter 2 inhibitors treatment: A meta-analysis.J Diabetes Investig2018https://conductscience.org/library/papers/29029369PubMed
1725560730Transparent Reporting of a multivariable prediction model for Individual Prognosis or Diagnosis (TRIPOD): explanation and elaboration.Ann Intern Med2015https://conductscience.org/library/papers/25560730PubMed
1832324082Efficacy and safety of ertugliflozin across racial groups in patients with type 2 diabetes mellitus.Curr Med Res Opin2020https://conductscience.org/library/papers/32324082PubMed
1938836934Safety and effectiveness of SGLT2 inhibitors in a UK population with type 2 diabetes and aged over 70 years: an instrumental variable approach.Diabetologia2024https://conductscience.org/library/papers/38836934PubMed
2023344728Differences in the glucose-lowering efficacy of dipeptidyl peptidase-4 inhibitors between Asians and non-Asians: a systematic review and meta-analysis.Diabetologia2013https://conductscience.org/library/papers/23344728PubMed

See all 28 referencesDownload CSV of references

Cited by3

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 3 citations.

PMIDTitleJournalYearIn PapersSource
42511477Integrated Cytokine, Metabolic, and Proliferative Profiling Reveals Divergent Metabolic and Proliferative Responses in Papillary Thyroid Cancer Cells.Int J Mol Sci2026https://conductscience.org/library/papers/42511477PubMed
42502138Type 2 diabetes subtypes for precision medicine: methodological challenges and alternative prediction-based approaches.Diabetologia2026https://conductscience.org/library/papers/42502138PubMed
41952002Computational framework to quantify synergistic ligand activity in insulin secretion and resistance pathways in type 2 diabetes.J Comput Aided Mol Des2026https://conductscience.org/library/papers/41952002PubMed

Download CSV of cited by

Genes1

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn Genes
SLC5A26524PubTator's text mininghttps://conductscience.org/library/genes/6524

Source NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/41399804

GET https://conductscience.org/api/papers/v1/41399804/references?page=2